Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08046054 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PF-08046054 + pembrolizumab is an investigational combination therapy for advanced solid tumors. PF-08046054 (also known as SGN-PDL1V) is a PD-L1-directed antibody-drug conjugate (ADC) that consists of a monoclonal antibody targeting PD-L1, covalently linked via a protease-cleavable maleimidocaproyl-valine-citrulline (mc-vc) linker to the microtubule-disrupting agent monomethyl auristatin E (MMAE). The ADC enables selective delivery of MMAE to PD-L1-expressing tumor cells; the intended mechanisms are cytotoxicity, immunogenic cell death, and bystander effect, while PD-1/PD-L1 checkpoint inhibition is considered unlikely. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting PD-1. The combination aims to enhance antitumor immune responses and direct cytotoxicity in metastatic or unresectable solid tumors[1][2][3][4][6].
- Other names
- PF-08046054 + pembrolizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PF-08046054 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-08046054 + pembrolizumab.